close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Amylyx Pharmaceuticals, Inc.

< Previous 1 2 3 4 Next >
News headline image
Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
News headline image
Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
News headline image
Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
News headline image
Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
News headline image
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
News headline image
Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
News headline image
Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
News headline image
Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
News headline image
Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
News headline image
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
News headline image
Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
News headline image
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
News headline image
Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
News headline image
Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
News headline image
Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
News headline image
Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
News headline image
Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
News headline image
Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
News headline image
Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
News headline image
Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
News headline image
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
News headline image
Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
News headline image
Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
News headline image
Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
News headline image
Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
News headline image
Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
News headline image
Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
News headline image
Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
News headline image
Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
News headline image
Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today